Nanomedicine for improvement of dendritic cell-based cancer immunotherapy

Purpose: Dendritic cell (DC)-based cancer immunotherapy has shown impressive outcomes, including the first FDA-approved anti-cancer vaccine, but clinical application faces challenges such as limited durable responses, antigen selection issues, and immunosuppressive tumor microenvironments. Nanoparticles (NPs) are promising for antigen/adjuvant delivery to DCs and can enhance T cell-stimulating effects while minimizing toxicity. This review surveys cancer immunotherapy with particular attention to NP-based delivery methods targeting DCs.

Hypothesis: No formal experimental hypothesis. Central thesis: NP-based delivery can improve DC vaccine efficacy by targeting antigens and adjuvants to DCs, activating DCs, and modulating the immunosuppressive tumor microenvironment, thereby enhancing anti-tumor T cell responses.

Aims: Provide a comprehensive examination of the role of nanomedicine in improving the efficacy of DC vaccines. - Survey cancer immunotherapy with particular attention to NP-based delivery methods that target DCs. - Discuss strategies for DC targeting by NPs, activation of DCs by NPs, and overcoming DC vaccine limitations. - Highlight physicochemical NP factors (size, shape, charge, surface) that influence DC uptake and immune responses.

Delivery system: NP types: polymeric NPs (PLGA, PEI, PLGA-PEI, chitosan, mannosylated chitosan, γ-PGA, pH-sensitive micelles, poly(propylene sulfide), gelatin), lipid/liposomal systems (mannan-coated liposome-protamine-DNA, PEGylated liposomes), inorganic NPs (gold with polyelectrolyte multilayers, iron oxide-zinc oxide core-shell, single-wall carbon nanotubes), and others. - Payloads: tumor antigens (OVA, TRP2, hgp100, HPV E7, WT1, CEA), adjuvants/TLR agonists (CpG ODN, MPLA, R848, poly I:C, imiquimod R837, 7-acyl lipid A), siRNA (STAT3, SOCS1, PD-L1, CD73), plasmid DNA (IL-12), cytokines, and antibodies/ligands. - Targeting/functionalization: anti-DEC-205, anti-CD40, mannose/mannan, DC-SIGN, Fc receptor, and DC surface receptors (DEC-205, mannose receptor, CD11c, CD40). - Size considerations: 10–50 nm for lymph node targeting; 100–200 nm for tumor microenvironment accumulation; <50 nm for efficient DC antigen/adjuvant delivery; NPs >100 nm show reduced tumor-draining lymph node targeting.

Approach: Review of preclinical and clinical literature; no primary experiments. In vitro systems include DCs, RAW264.7, J774, B16, CT26, EG7-OVA, TC-1, MC38/CEA, and ID8-Defb29/Vegf-A cells. In vivo models include B16 melanoma, 4T1 breast cancer, CT26 colon cancer, EG7-OVA lymphoma, TC-1 HPV tumor, MC38/CEA, and ID8 ovarian carcinoma mouse models. Clinical context includes approved cancer vaccines such as Sipuleucel-T (Provenge) and Oncophage.

Key methods: NP characterization: size, zeta potential, TEM, fluorescence microscopy. - DC uptake, maturation, and activation: CD40, CD80, CD86, MHC I/II expression. - Cytokine secretion: IL-12, TNF-α, IFN-γ, IL-6, IL-2. - T cell assays: antigen-specific CTL responses, T cell proliferation, cross-presentation, IL-2 secretion. - In vivo: tumor growth inhibition, survival, DC migration tracking (e.g., indocyanine green), MRI, histology. - Gene silencing: STAT3, SOCS1, PD-L1, CD73 siRNA knockdown.

Key results: PLGA NPs conjugated/loaded with Hp91 increased DC activation via CD40/CD80 upregulation and IL-6 secretion; in HER2-specific CD8+ T cells, this arrested tumor growth and increased survival. - PLGA NPs loaded with melanoma peptides (hgp10025–33 and TRP2180–188) plus MPLA delayed tumor growth in a prophylactic B16 melanoma model; combining with IFN-γ further improved anti-tumor potential. - STAT3 siRNA + TLR7 ligand R837 in PLGA NPs (146 nm, −22 mV) enhanced DC maturation (CD40, CD80, IL-12, TNF-α), promoted DC migration to draining lymph nodes after 48 h, induced OVA-specific CTL responses, and caused tumor regression in EG7-OVA mice. - CD73 siRNA-loaded chitosan lactate NPs combined with tumor lysate-pulsed DC vaccine increased T cell proliferation, cytotoxicity, and cytokine production, and decreased tumor-infiltrating Tregs in 4T1 breast cancer-bearing mice. - PD-L1 siRNA PEI NPs (50 nm) suppressed PD-L1 in tumor-associated DCs, promoted DC maturation, increased survival in ovarian cancer, and increased central memory-like T cells in bone marrow. - Iron oxide-zinc oxide core-shell NPs (15.7 nm) loaded with CEA allowed DC antigen loading within 1 h and induced anti-CEA immune responses in an MC38/CEA murine cancer model. - Single-wall carbon nanotubes delivering WT1 peptide to APCs induced specific IgG responses.

Interpretation: Nanomedicine can improve DC-based cancer immunotherapy by facilitating antigen/adjuvant delivery to DCs, enhancing DC activation and T cell priming, and modulating the immunosuppressive tumor microenvironment. NPs can protect cargo, increase solubility, reduce toxicity, target lymph nodes/DCs, and enable co-delivery of antigens and adjuvants. However, little is known about efficacy in human cancer patients, and human studies are needed.

Limitations: Review article; no primary data. - Most studies are preclinical animal models; human data remain limited. - Substantial differences between animal models and human patients require further human studies. - DC vaccine limitations: activation state, antigen selection, limited durable responses, no consensus on ideal DCs, and expensive/time-consuming manufacturing. - NP limitations: size, shape, charge, and surface characteristics strongly affect biodistribution and uptake; PEGylation can reduce tumor cell uptake; passive targeting varies across patients and tumor types. - Potential toxicity and scale-up issues remain. - Few FDA-approved therapeutic cancer vaccines; many clinical trials have shown unsatisfactory results.